NYBCe and Chan Zuckerberg Biohub collaborate to build iPSC platform from cord blood for regenerative medicine
By Alina Maria Stan
Published on May 1, 2026.
The New York Blood Center Enterprises and Chan Zuckerberg Biohub are collaborating to derive induced pluripotent stem cell lines from cord blood, using NYBCe's inventory of over 30,000 units, including rare HLA-homozygous donors, and Biohub's expertise in reprogramming immune cells. The collaboration aims to address the gap between laboratory biology and scalable, immune-compatible treatments. The resulting cell lines will be shared research resources for regenerative medicine, disease modelling, and cell therapy. The global iPSC market is projected to grow from $2.6 billion in 2026 to $4.1 billion by 2031. Most iPSCs used in research are derived from skin cells or blood cells taken from individual donors, resulting in highly variable genetic backgrounds and immune profiles.
Related Articles
‘A ghost that lives with us’: Death Cafes take the sting out of the inevitable end
Death Cafes, popularized by social media, offer informal, unstructured conversations about death, offering alternative, realistic conversations about experiences and spiritual support for dying individuals.
High school teams form prayer circle for student experiencing medical emergency
A group of high school athletes gathered at Huntington to pray for a recovering student after a medical emergency that led to his death.
Oh No, Apparently Gen Z Thinks Cigarettes Are Cool Again
Aristen's popularity among Gen Z is high, and despite federal cuts, many are shifting focus to other aspects of life, particularly regarding smoking, which are often linked to crime.